Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   20:12
0,510 USD (+0,51%)
(+0,51%)   20:12
Grafiek Nektar Therapeutics Grafiek Nektar Therapeutics

Nektar Therapeutics in het nieuws

7 november 2023 · Nektar Therapeutics Reports Third Quarter 2023 Financial Results · Persbericht

31 oktober 2023 · Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets · Persbericht

13 oktober 2023 · Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress · Persbericht

2 oktober 2023 · Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy · Persbericht

27 september 2023 · Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer · Persbericht

13 september 2023 · Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis · Persbericht

7 september 2023 · Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th · Persbericht

8 augustus 2023 · Nektar Therapeutics Reports Second Quarter 2023 Financial Results · Persbericht

7 augustus 2023 · Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company · Persbericht

2 augustus 2023 · Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets · Persbericht

Profiel Nektar Therapeutics

Biotechnologie
Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.nektar.com

Hoofdzetel: San Francisco, California vlag Verenigde Staten

CEO: Howard Robin

Werknemers: 820

Aandelen Nektar Therapeutics

Beurswaarde: 96,80 miljoen USD

Effecten: 190,77 miljoen

Winst per aandeel (12 maand):  PLUS

Beta: 2,36

Mijn selecties